ArticleDiscover oncology2025
Identification of KIF14 as a ferroptosis biomarker for predicting the prognosis and immunotherapy efficacy of bladder cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFerroptosis, a recently recognized form of regulated cell death, plays a prominent role in anti-tumor immunity. However, the potential functions of ferroptosis-related regulators in the prognosis, immune checkpoint genes expression, and immunotherapy efficacy of bladder cancer (BC) have not been systematically studied. MATERIALS AND
methodsWe systematically evaluated the correlations between ferroptosis levels and prognosis, clinical characteristics, tumor mutation burden (TMB), immune checkpoint gene expression, and immune cell infiltration characteristics. The ferroptosis level of each patient was calculated using principal component analysis based on the expression of prognostic differentially expressed genes. Hub ferroptosis-related genes involved in immunoregulation and immunotherapy efficacy in BC were subsequently identified.
resultsEighteen ferroptosis regulators were associated with the prognosis of BC. We identified three ferroptosis subgroups, which have different immune cell infiltration characteristics and distinct carcinogenesis-related immune pathways, such as immune cell differentiation, and the PD-L1/PD-1 pathway. High ferroptosis levels and ferroptosis-related gene kinesin family member 14 (KIF14) are closely associated with poor prognosis, tumor mutation burden, immune checkpoint genes expression, and immune cell infiltration. An immunotherapy cohort confirmed that patients with high KIF14 expression demonstrated significant therapeutic and clinical benefits.
conclusionsThe study revealed that ferroptosis level and KIF14 were significantly related to prognosis, immune checkpoint genes expression, immune cell infiltration, and immunotherapy response in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.